HEPATOCELLULAR CARCINOMA (HCC)

This early-phase study tests a personalized mRNA cancer vaccine (XH001) given alongside standard treatment after surgery for people with high-risk solid tumors (bile duct, gallbladder, pancreatic, liver, or stomach cancer). The main goals are to check safety and see if the vaccin…

This study tests a new drug called pumitamig, alone or with another drug (ipilimumab), in people with advanced liver cancer that cannot be removed by surgery. The trial includes 198 participants who have not had prior cancer treatment. The goal is to see if the drugs are safe and…

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This study tests whether combining procedures that block blood flow to liver tumors (TACE or HAIC) with targeted drugs and immunotherapy can help control advanced hepatocellular carcinoma that cannot be surgically removed. The trial enrolls adults aged 18–80 with large or vein-in…

This early-stage study tests a new drug called CBA-1205 in people with advanced solid tumors (like liver cancer or melanoma) that have not responded to other treatments. The main goal is to check the drug's safety and find the best dose. About 66 participants will receive the dru…

This study tests whether adding the drug lenalidomide to ongoing targeted therapy and immunotherapy can help people with advanced liver cancer whose disease has worsened after multiple prior treatments. About 32 participants will receive the combination and be monitored for tumor…

This early-stage trial tests an experimental drug called CTX-10726 in about 70 people with advanced gastroesophageal, liver, endometrial, or kidney cancers that have stopped responding to standard treatments. The main goal is to check safety and find the right dose. Participants …

This early-phase trial tests an experimental oral drug called ST-01156 in adults with advanced solid tumors that have spread or cannot be removed by surgery. The drug works by breaking down a protein inside cancer cells. The main goals are to find a safe dose and check for side e…

This study tests a combination of three drugs—chemotherapy infused directly into the liver, a targeted pill, and an immunotherapy—in 38 people with advanced liver cancer that has spread into the main portal vein. The goal is to shrink the tumor enough so that surgeons can remove …

This study tests whether adding the experimental drug fostrox to the standard drug lenvatinib helps shrink tumors or slow cancer growth in people with advanced liver cancer. About 80 adults whose cancer worsened after initial immunotherapy will be randomly assigned to receive eit…

This program offers early access to a combination of two immunotherapy drugs, botensilimab and balstilimab, for people with serious or life-threatening cancers like colorectal, pancreatic, lung, liver, melanoma, sarcoma, ovarian, or prostate cancer. It is for patients who have tr…

This study tests whether a sequence of treatments—chemotherapy infused into the liver, two drugs (durvalumab and bevacizumab), and targeted radiation—can shrink advanced liver cancer enough to allow surgery. About 30 adults with liver cancer that cannot currently be removed will …

This trial tests whether a computer guidance software can help doctors more completely destroy liver tumors during microwave ablation. About 84 adults with liver cancer (HCC) will have the procedure with the software's assistance, and their outcomes will be compared to historical…

This study tests a combination of two drugs—tislelizumab (an immunotherapy) and huaier granule (a traditional Chinese medicine)—as a first treatment for people with advanced liver cancer that cannot be surgically removed. About 94 adults will receive this combination to see if it…

This study tests whether a drug called polyene phosphatidylcholine, given before and after surgery, can protect the liver in people with liver cancer. About 96 participants will receive either the drug combo or standard care. The goal is to see if it reduces liver injury after la…

This phase 3 trial tests whether drug-eluting bead chemoembolization (DEB-TACE) works better than conventional chemoembolization (cTACE) for liver cancer patients who have had a TIPS procedure to manage complications of cirrhosis. The study will enroll 206 participants and track …

This pilot study tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) and focused radiation before surgery in 15 people with advanced liver cancer that is borderline removable. The goal is to see if this approach is safe and can shrink tumors enough to allow …

This study tests a combination of a standard liver cancer procedure (TACE) with three immunotherapy drugs (sintilimab, bevacizumab, and ipilimumab) in 36 adults with advanced liver cancer that cannot be removed by surgery. The goal is to see if this mix is safe and works better t…

This Phase 2 trial is testing whether adding a targeted chemotherapy infusion into the liver (HAIC) to a combination of two drugs—sintilimab (an immunotherapy) and bevacizumab biosimilar (which blocks blood vessel growth)—helps people with advanced liver cancer live longer withou…

This study tests a combination of two drugs, IBI310 and sintilimab, as a first treatment for people with advanced liver cancer that cannot be removed by surgery. About 680 participants will receive either the combination or standard care. The goal is to see if the combination shr…

This study tests a new method to check if a liver cancer treatment called radioembolization is safe for the lungs. Currently, doctors use a test particle (MAA) to estimate lung radiation risk, but it may not be perfectly accurate. The new method uses a small 'scout dose' of the a…

This study tests two new drugs: one to help spot liver cancer cells (RYZ811) and another to deliver treatment directly to them (RYZ801). It is for people with a type of liver cancer called GPC3-positive hepatocellular carcinoma that cannot be removed by surgery. The goal is to se…

This study tests whether people with large liver cancer (over 5 cm) can get their entire radioembolization treatment in a single day. Normally, planning scans and treatment are done on separate days. The procedure involves injecting tiny radioactive beads into the liver's blood s…

This clinical trial compares two types of radiation therapy—SBRT and SIRT—each combined with immunotherapy, for people with advanced liver cancer that cannot be removed by surgery. About 106 participants will be randomly assigned to one of the two treatments. The goal is to see w…

This study tests a faster version of radioembolization for people with small liver cancers (5 cm or less). Normally, doctors do a pre-treatment scan to check for lung risks, but this trial skips that step for carefully selected patients. The goal is to see if the simplified appro…

This study tests a personalized mRNA vaccine (iNeo-Vac-R01) made from each patient's tumor, combined with an immunotherapy drug (PD-1 inhibitor), to prevent liver cancer from coming back after surgery. About 20 adults with early-stage liver cancer will receive the treatment. The …

This study tests whether two drugs, sintilimab and bevacizumab, given after surgery can prevent cancer from coming back in people with ruptured liver cancer. About 35 participants will receive the combination every three weeks. The goal is to see if this approach is safe and impr…

This phase 2 trial is testing a combination of two immunotherapy drugs (AK104 and AK112) plus a targeted pill (TT-00420) in 100 people with advanced hepatocellular carcinoma that cannot be treated with local therapies. The main goal is to see how many patients' tumors shrink. Par…

This study tests a new drug called HLX13, which is a biosimilar (a very similar copy) of the approved immunotherapy YERVOY, in people with advanced liver cancer that cannot be removed by surgery. The trial will compare HLX13 to the original YERVOY, both given alongside another im…

This study is for people with advanced liver cancer who are starting a combination of two drugs (atezolizumab and bevacizumab). It will test if adding a procedure called TIPS (which places a small tube in the liver to improve blood flow) can help keep the liver working better for…

This early-phase trial tests a new drug called Sapu003, given with or without exemestane, in adults with advanced cancers that respond to mTOR pathways—including certain breast, kidney, liver, and neuroendocrine tumors. The main goal is to find the safest dose and check for side …

This early-phase trial is testing a new drug called CREPT-618 in 13 adults with advanced liver cancer who have not responded to standard treatments. The drug works by targeting a gene called CREPT, which may help control tumor growth. The main goals are to check safety, find the …

This study tests whether giving a specific chemotherapy cocktail (mFOLFOX) directly into the liver artery after surgery can prevent liver cancer from coming back in patients at high risk. About 30 adults who had their liver cancer removed will receive up to two rounds of this inf…

This phase 2 trial is testing whether a combination of Icaritin soft capsules and a liver-directed chemotherapy infusion (mFOLFOX) can prevent hepatocellular carcinoma from coming back after surgery in patients with high-risk features. About 30 participants will receive the treat…

This study tests a new drug called ABSK-011 for people with advanced liver cancer that has not responded to prior treatments. The drug targets a specific protein (FGF19) found in some tumors. About 141 participants will receive either ABSK-011 plus standard care or a placebo plus…

This phase 2 trial tests a DNA vaccine called NWRD06 in 30 people with a specific type of liver cancer (GPC3-positive) who have had surgery to remove their tumors. The vaccine is given as a shot followed by a mild electric pulse to help it enter cells. The goal is to see if it ca…

This phase 2 trial tests whether adding FOLFOX chemotherapy to the existing immunotherapy drugs atezolizumab and bevacizumab can help patients with advanced liver cancer whose disease has worsened on first-line treatment. The study will enroll 30 adults with Barcelona Clinic Live…

This phase 3 trial tests whether combining radiotherapy with the immunotherapy drug sintilimab can better prevent liver cancer from coming back after surgery, compared to the standard TACE procedure. The study enrolls 286 adults with high-risk features like narrow surgical margin…

This study tests whether combining a liver-directed procedure (TACE) with the drug icaritin can help prevent liver cancer from coming back after surgery in patients at high risk of recurrence. Thirty adults who had their liver cancer completely removed will receive up to 4 TACE t…

This phase 2 trial tests whether giving a combination of targeted therapy (apatinib), immunotherapy (camrelizumab), and a procedure called TACE before surgery can help shrink centrally located liver tumors in people with stage B liver cancer. The goal is to make surgery more effe…

This study tests a new radioactive tracer called 68Ga-GPC3 that targets a protein found on liver cancer cells. About 40 adults with suspected or confirmed hepatocellular carcinoma will receive both this new tracer and a standard tracer (18F-FDG) for PET/CT scans. Researchers will…

This study aims to create a simple blood test to find liver cancer at an early, more treatable stage. Researchers will analyze genetic material in the blood of 600 adults, including those with liver cancer, chronic liver disease, and healthy volunteers. The goal is to improve ear…

This study is testing whether adding a special PET scan (using F18-Piflufolastat) to standard imaging can better diagnose and stage liver cancer. Researchers will enroll 90 veterans with suspected or confirmed hepatocellular carcinoma. The goal is to see if the scan helps clarify…

This study is testing whether a blood test that looks for a marker called mSEPT9 can predict liver cancer in people with cirrhosis. Researchers will follow 400 patients for up to 5 years, taking blood samples every 6 months to see if changes in this marker signal cancer risk. The…

This pilot study is testing a new radioactive tracer called 89Zr-TLX250, which targets a protein (CAIX) found on certain tumor cells. The goal is to see if PET-CT scans using this tracer can detect more tumor lesions in people with liver cancer, bile duct cancer, or neuroendocrin…

This study is testing a new imaging agent called 18F-T2, which is designed to highlight tumors that produce a protein called CAIX. About 200 adults with various cancers (like kidney, lung, or breast cancer) will receive an injection of 18F-T2 and then undergo a PET/CT scan. The g…

This study tests whether an artificial intelligence (AI) model can help doctors more accurately stage and choose treatments for liver cancer (hepatocellular carcinoma). About 108 patients and doctors from different hospitals will participate. Doctors will make decisions with and …

This study tests whether a new type of PET scan that uses two different tracers at the same time can find and stage liver cancer and pancreatic neuroendocrine tumors better than standard single-tracer scans. Researchers will compare the number and location of tumors seen with the…

This study is developing a blood test that looks for tiny genetic molecules called miRNAs, which can signal the presence of several gastrointestinal cancers like liver, pancreatic, and colorectal cancer. Researchers will analyze blood samples from 1,000 adults—half with cancer an…

This study is testing an artificial intelligence system that analyzes CT scans to predict microvascular invasion (MVI) in liver cancer patients. MVI is a key sign of aggressive cancer that currently can only be confirmed after surgery. The AI tool aims to give doctors this inform…

This study is testing whether offering a liver ultrasound and blood test every 6 months to people with cirrhosis can catch liver cancer early and reduce deaths. About 617 adults aged 40-79 with compensated cirrhosis (no severe complications) in one region of Denmark will be offer…

This trial tests whether a smartphone app that tracks symptoms can improve quality of life for 500 liver cancer patients receiving immunotherapy. Patients in the intervention group report symptoms weekly via the app, which gives personalized advice and alerts doctors if scores ar…

This study aims to build an AI model that uses medical images and tissue samples to predict which liver cancer patients will benefit from additional treatments after surgery. Researchers will analyze data from 11,000 patients to see if the AI's recommendations match real-world ou…

The JADE study is a large registry that will follow 1,000 people with liver or bile duct cancer in Germany. Its goal is to collect information on how these cancers are actually treated in routine care, including treatments, outcomes, and patient quality of life. No experimental d…

This study looks at ways to personalize treatment for people with liver cancer (hepatocellular carcinoma). Researchers want to find out which patients are likely to respond to immunotherapy by testing their tumor tissue and blood before treatment starts. The goal is to avoid givi…

This study looks at whether a patient's emotional state—like depression or anxiety—affects how well advanced liver cancer treatment works. Researchers will follow 90 people with liver cancer who are getting a combination of chemotherapy, targeted therapy, and immunotherapy. They …

This observational study is looking at whether certain substances in the blood can help predict and monitor how liver cancer responds to a treatment called TACE. Researchers will collect blood samples from 15 adult patients before and after TACE and compare them with standard ima…

This study is developing a computer-based planning tool to make transarterial radioembolization (TARE) more predictable for liver cancer patients. TARE delivers tiny radioactive beads directly to tumors, but results vary due to complex blood vessel patterns. Researchers will crea…

This study is testing whether a blood test (liquid biopsy) can predict how well liver cancer responds to a type of internal radiation called Y90 radioembolization. Researchers will take blood samples from 12 adults with liver cancer before and after treatment to look for tumor ce…

This study looks at 600 adults with liver cirrhosis to see if a shorter MRI scan works better than ultrasound for finding early liver cancer. Researchers will also track body composition and other health changes over time. The goal is to improve how doctors monitor and predict li…